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Introduction
Homeostasis in the mammary gland is achieved by a
balance between cell proliferation and cell death (apopto-
sis), which is reflected by an organized tissue structure.
Breast cancer, which is a loss of tissue homeostasis, is
characterized by perturbations in mammary tissue archi-
tecture, that is linked to alterations in the extracellular
matrix (ECM) and in the adhesion molecules expressed by
the MECs [1]. Correcting the adhesion defects in the
mammary tumor epithelia can restore tissue organization
and normal behavior to some breast tumor cells [2]. Con-
versely, altering the stromal microenvironment of the
breast promotes the expression of tumorigenic potential in
MECs [3]. This suggests that aspects of the breast cancer
phenotype arise from alterations in the dynamic interplay
between the epithelial cells, the mammary stroma, and the
structural organization of the breast. Gaining an under-
standing of how disturbances in this relationship relate to
the pathogenesis of human breast cancer will depend on
delineating the subtleties of this dialog. This will require
the application of appropriate model systems that can
reconstitute stromal–epithelial interactions in the context
of a three-dimensional tissue structure.
Breast cancers typically exhibit low rates of cell prolifera-
tion (apoptosis deregulation), often recur after years of
dormancy (apoptosis evasion), and once re-established
frequently acquire resistance to treatment (apoptosis
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resistance). As such, alterations in apoptosis probably
predominate in the pathogenesis of human breast cancer.
Therefore, an understanding of how the stroma influences
adhesion and tissue architecture to modulate MEC sur-
vival, and how these pathways become deregulated in
mammary tumors, should help to define the critical events
that regulate breast cancer pathogenesis. In the present
brief review, we discuss how altered stromal–epithelial
interactions and changes in cell adhesion and tissue
architecture influence MEC survival to drive malignant
transformation in the breast. We then present data that
suggest that the interplay between the tissue microenvi-
ronment, cell adhesion, and tissue architecture may also
underlie the origins of the multidrug resistant breast
tumor phenotype.
Cell adhesion and survival in mammary
epithelial cells
Normal cells require adhesion to grow and survive, and
anchorage independence for growth and survival is con-
sidered a key feature of transformed cells [4]. Consistent
with this concept, primary and immortalized nontrans-
formed human and murine MECs require adhesion to an
ECM basement membrane (BM) in order to maintain
their survival in culture. For example, both primary and
immortalized MECs will retain their viability ex vivo in the
presence of growth factors such as insulin-like growth
factor-I and epidermal growth factor, provided that they
are in contact with a laminin-rich BM [5]. This response
is specific, because primary MECs on fibronectin or in a
collagen I ECM will undergo apoptosis [6–8].
The mechanism by which adhesion to a laminin-rich BM
mediates MEC survival is not completely known, but liga-
tion and activation of the laminin receptor a3b1 integrin is
believed to be a part of the process [7,9]. Ligation of MEC
b1 integrins alters the activity of adhesion-associated
kinases, such as focal adhesion kinase and integrin-linked
kinase [4,6,10]. BM-mediated survival in MECs probably
requires co-operative signaling with cytokine receptors,
such as the insulin receptor [5] or the epidermal growth
factor receptor (EGFR) [11]. Synergistic interactions
between growth factor receptors and integrins in MECs
presumably lead to the activation of downstream effectors
such as phosphinositide 3-kinase (PI3-K), mitogen-acti-
vated protein kinase and/or nuclear factor-kB [6,12].
These enzymes in turn are functionally linked to pathways
that can actively repress death by modulating the expres-
sion and/or activity of various apoptosis repressors,
including members of the bcl-2 family [13]. In primary and
immortalized murine MECs, for example, adhesion-depen-
dent survival is associated with PI3-K induced repression
of bax translocation to the mitochondria [14]. Moreover,
integrin-linked kinase can stimulate Akt activity via PI3-K,
and this in turn can influence murine MEC survival by alter-
ing the functional status of BAD [10,15].
Whether BM-directed integrin-linked pathways also
operate to mediate MEC survival in the mammary gland
has not been directly established. Nevertheless, there is
good concordance between remodeling of the mammary
gland in vivo and expression of genes associated with
involution (apoptosis) [16]. Furthermore, loss of mammary
gland function and apoptosis also correlate with increased
expression of metalloproteinases, which are ECM-degrad-
ing enzymes. Indeed, parallel studies conducted ex vivo,
using MECs ectopically expressing the metalloproteinase
stromelysin-1 [17], directly demonstrated that acute expo-
sure to metalloproteinases and rapid degradation of the
BM would lead to apoptosis.
It should be noted that two waves of apoptosis occur
during involution in the mammary gland. The first wave,
or initiation stage, of apoptosis involves the death of a
small population of differentiated MECs, and probably
occurs as a consequence of changes in systemic hor-
mones and/or mechanical forces. The second stage
involves the death of the remaining acinar MECs, and is
linked to the activation of metalloproteinases, ECM
degradation, and the irreversible commitment to remodel
the mammary gland [16]. The precise roles of cell adhe-
sion and integrin signaling in either of these stages of
involution have not been well defined. Nevertheless, it
was reported [18] that chronic exposure of MECs to
stromelysin-1 both in vivo and in culture resulted in
malignant transformation, suggesting that MECs that cir-
cumvent BM-dependent survival are tumorigenic.
Whether malignant transformation in the breast requires
absolute independence from adhesion-linked survival
cues is yet to be determined.
Anchorage independence for survival and
malignant transformation of the breast
The perception that anchorage independence for survival
is an essential feature of malignant breast tumors is con-
sistent with reports that immortalized breast tumor cells
are able to grow and survive in soft agar. More specifically,
we and others have found that malignant human MECs no
longer depend on ligation and activation of b1 integrins for
survival in culture [2,7,9]. Using a tumor progression
model called HMT-3522, in which it is possible to study
the early changes that occur during malignant transforma-
tion [1], we found that as the nontransformed cells in this
series progress towards malignancy, they gradually lose
their dependency upon b1 integrin for survival [7]. This
suggests that circumvention of b1 integrin adhesion-
dependent survival signaling may play a critical role in
driving malignant transformation of the breast.
More recently, we determined that loss of b1 integrin
dependency for survival in this cell series is associated
with a dramatic increase in the expression and activity of
EGFR (Weaver et al, unpublished data). We also foundBreast Cancer Research    Vol 3 No 4 Chrenek et al
that inhibiting the activity of the EGFR was sufficient to
revert the malignant phenotype of the tumor cells and
repress their anchorage independence for growth and sur-
vival [19]. Alterations in b1 integrin-dependent survival and
EGFR activity occur concomitantly with a perturbed ability
of the HMT-3522 cells to form breast tissue-like structures
in response to a reconstituted BM (Weaver et al, unpub-
lished data). This emphasizes the existence of an associa-
tion between cell adhesion-directed tissue architecture,
growth control, and apoptosis regulation in MECs. These
findings also imply that deregulation of this relationship
could lead to malignant transformation.
Is anchorage independence necessary for
malignant transformation in mammary
epithelial cells?
Clinical data support the idea that independence from
BM-directed survival is linked to malignant transformation
in the breast. Immunologic studies [20] have shown that
invasive breast tumor cells exhibit a reduced level of
apoptosis when compared with cells located in benign
ductal carcinoma in situ (DCIS) lesions. Similarly, intense
staining for focal adhesion kinase, a tyrosine kinase that
can induce anchorage-independent survival in epithelial
cells, was detected both in invasive tumor cells and in
groups of premalignant cells within adjacent DCIS
lesions [21]. Unfortunately, these data do not establish
whether the enhanced survival in the transformed cells is
due to genetic selection or is mediated via microenviron-
mental factors.
Although genetics undoubtedly plays a critical role in driving
malignant transformation and apoptosis resistance in the
breast, evidence is slowly accumulating that microenviron-
mental factors must also play a role in these processes. For
example, angiogenesis can enhance mammary tumor viabil-
ity, irrespective of genetic selection [22], whereas nonmalig-
nant MECs exposed to a reactive stromal ECM can be
induced to develop a tumor-like behavior in the absence of
genetic events [3]. Indeed, stromal fibroblasts associated
with mammary tumors have been shown to display a ‘fetal-
like’ behavior, and this altered phenotype has been sug-
gested to modify significantly the kinetics of tumor
progression [23]. Interestingly, data show that primary
human breast tumors frequently exhibit a decrease in the
expression of the ‘differentiation-associated’ laminin/colla-
gen integrin receptors a2, a3, and b1, but they often express
the ‘invasion and growth-linked’ tenascin and fibronectin
receptors av integrin and a5 integrin [1]. Some aggressive
breast tumors even retain expression of the laminin integrins
a6 and b4, and secrete BM proteins [24].
Because MECs within DCIS lesions seldom show
changes in their integrin expression, this indicates that
the dramatic shifts in integrin expression may be neces-
sary to support tumor cell survival and drive malignant
transformation. Although one could argue that the
changes in integrin expression are solely due to selection
of a genetically variant population of cells, it is also possi-
ble that the altered integrin expression observed in breast
tumors reflects a dynamic adaptive survival response by
the tumor cells to the interstitial stromal ECM. This would
depend on the ability of the tissue microenvironment to
modulate integrin expression and apoptosis resistance
epigenetically in MECs.
In support of this concept, significant and rapid changes
in integrin expression have been documented in primary
tumor cells before (in tumors in situ that are in contact
with a reactive stromal ECM) and after growth within a
reconstituted BM ex vivo [25]. We and others [19,26,27]
have also observed that the ECM microenvironment can
dynamically modulate integrin expression in both primary
and immortalized MECs. Most recently, we found that
malignant transformation and b1 integrin independence in
the HMT-3522 tumors occurs in conjunction with, and is
dependent on, ligation of a6b4 integrin and secretion of
BM protein (Zahir et al, unpublished data). These results
are consistent with reports that high levels of expression
of a6 and b4 integrins, and BM proteins in human breast
carcinomas correlate with reduced patient survival, and
functional deletion of a6 integrin in metastatic breast
tumor cells results in a significantly higher rate of apopto-
sis [24,28,29]. Therefore, a more realistic interpretation
regarding the evolution of apoptosis resistance and
malignant transformation in the breast is that it arises by a
combination of genetic ‘mutation/selection’ pressures
and epigenetic ‘adaptation’ responses induced by the
tissue microenvironment.
Studies conducted with isolated primary human breast
tumor cells support the idea that stromal–epithelial inter-
actions are primarily responsible for promoting survival in
primary breast tumors in vivo, as opposed to cell
autonomous ‘selection’ events. ‘Tumorigenic’ breast cell
lines isolated from primary breast tumors that represent
earlier, less aggressive breast cancer phenotypes do not
always exhibit true anchorage independence for growth
and survival. Indeed, the majority of immortalized tumor
cells used to study apoptosis regulation and anchorage
independence in human breast cancer have been gener-
ated from late-stage disease cells isolated from metasta-
tic pleural effusions, in which stromal interactions are
minimal and cell–cell interactions are predominant [30].
Along this vein, Giovanella et al [31] reported that a mere
6.1% (16/262) of primary infiltrating duct-cell human
breast carcinomas survived and grew following injection
into nude mice. Only cells from those tumors that were
highly cellular (enhanced cell–cell interactions) and
lacked detectable desmoplastic hyperplasia (minimal
stromal involvement) could be grown and serially trans-
planted into nude mice.Interestingly, primary breast tumor cells that are first
embedded within purified extracellular collagen I or a
reconstituted BM can be successfully grown and propa-
gated in nude mice [32]. It has also been observed that
primary human breast tumor cells can be maintained and
effectively studied ex vivo if the cells are maintained in the
presence of either a reconstituted BM or purified collagen
I matrix [33,34]. Therefore, a more prudent conclusion
regarding malignant transformation and apoptosis resis-
tance in breast cancer is that, rather than acquiring
absolute anchorage independence for survival, most
primary human mammary tumors probably depend on
altered stromal factors and/or adhesive interactions to
maintain their viability in vivo.
Cell adhesion, tissue architecture and
apoptosis resistance in breast cancer
Breast tumors characteristically lack tight junctions [35],
and exhibit disrupted E-cadherin organization [1]. These
observations are consistent with the idea that loss of
cell–cell adhesion is essential for tumor invasion [36].
However, aggressive breast tumors with a poor prognosis
often upregulate different cell adhesion molecules such as
P-cadherin, CD44, and Ep-Cam [37–39], and readily
aggregate. Enhanced cell–cell interactions can repress
apoptosis [40], and the success of culturing primary
breast tumor cells ex vivo in three dimensions may be
explained in part by the augmentation of nonclassical inter-
cellular communication in the spheroid cultures [41]. A
relationship between multicellular-mediated drug resis-
tance, the metastatic phenotype, and cell adhesion has
also been established [42]. These findings suggest that
altered intercellular communication in breast tumors may
be another mechanism whereby BM independence and
apoptosis resistance can be generated in breast tumors.
It is not known how intercellular interactions support cell
survival. However, Carmeliet et al [43] showed that VE-
cadherin functionally interacts with the vascular endothe-
lial growth factor receptor, PI3-K, and active Akt in a
physical complex to mediate endothelial cell survival in
vivo. Green fluorescent protein tagged protein kinase B/
Akt, which facilitates adhesion directed survival in MECs,
also localizes to both cell–ECM and cell–cell junctions
[44]. Furthermore, the retinoblastoma protein, which is
implicated in ECM-directed survival, mediates adherens-
junction-dependent survival in MECs [45]. Thus cell–cell
adhesion probably supports MEC survival by actively
repressing apoptosis via cross-talk with growth factor and
ECM-linked survival pathways.
We and others have shown that long-term survival and
apoptosis resistance in MECs in a reconstituted BM is
dependent on the formation of a multicellular tissue-like
structure and the assembly of adherens junctions (Weaver
et al, unpublished data) [46]. Studies have shown that
acquisition of the multidrug-resistant phenotype can be sig-
nificantly accelerated if the tumor cells being studied are
grown as three dimensional spheroids [42]. Tumor cells
grown as three dimensional spheroids exhibit enhanced
cell–cell communication, change their integrin expression,
and secrete ECM proteins [41,47]. This indicates not only
that cell–cell interactions could modulate ECM-directed
survival via integrin and growth factor receptor mediated
events, but also that such cross-talk may additionally confer
apoptosis resistance on MECs.
Conclusions
The molecular basis for the cross-modulation of survival
networks by cell–cell and cell–ECM interactions remains
ill defined. Cells dramatically reorganize their cytoarchitec-
ture when cultured as three dimensional apoptosis resis-
tant spheroids, however, and perturbing cytoskeletal
organization restores their apoptosis sensitivity (Weaver et
al, unpublished data). Because actin modifiers can regu-
late cell survival [48], and are themselves altered during
apoptosis [49], this indicates that the regulation of apop-
tosis by cell adhesion cross-talk probably depends on the
cytoskeleton and its molecular regulators. Nevertheless,
the existence of dynamic and reciprocal cross-modulation
of apoptosis by cell–cell and cell–ECM implies that any
significant change in the breast stromal ECM, or in the
adhesion molecules expressed by the breast epithelium,
will have some impact on MEC survival and/or apoptosis
sensitivity. Should alterations in any one or more of the
adhesion-linked apoptosis regulatory network components
confer enough of a survival advantage to the cells, then
this could favor MEC viability in the absence of a BM, and
thereby promote malignant transformation. If the changes
were of sufficient magnitude, then they could even render
some breast ‘tumor’ cells resistant to exogenous apoptotic
stimuli, and hence give rise to the multidrug-resistant
breast cancer phenotype. Indeed, this paradigm can
explain the profound effects exerted by a reactive stroma
on cancer progression, and why the site of tumor metasta-
sis can exert such a strong influence on the efficacy of
cancer treatment.
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